Clinical trial results:
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies

Summary

EudraCT number	2021-002037-42
Trial protocol	DE SE FR
Global end of trial date	24 November 2024

Results information

Result version number	v1 (current)
This version publication date	28 June 2025
First version publication date	28 June 2025

Trial information

Trial identification

Sponsor protocol code	C5771001

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04993677
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Seagen Inc.
Sponsor organisation address	21823 30th Drive S.E., Bothell, United States, 98021
Public contact	Chief Medical Officer, Seagen Inc., 1 8554732436, medinfo@seagen.com
Scientific contact	Chief Medical Officer, Seagen Inc., 1 8554732436, medinfo@seagen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 February 2025
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	24 November 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the antitumor activity of SEA-CD40 combined with other therapies.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 October 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 60
Country: Number of subjects enrolled	Germany: 5
Country: Number of subjects enrolled	Spain: 5
Country: Number of subjects enrolled	Sweden: 4
Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Canada: 1
Worldwide total number of subjects	77
EEA total number of subjects	16

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	39
From 65 to 84 years	36
85 years and over	2

Subject disposition

Recruitment

Recruitment details:

This study planned to have 5 cohorts-Cohort 1: relapsed/refractory melanoma, Cohort 2: uveal melanoma, Cohort 3: programmed cell death 1 ligand 1 (PD-[L]1)-naive melanoma, Cohort 4: non-small cell lung cancer (NSCLC), programmed cell death ligand 1 (PD-L1) 1-49%, Cohort 5: NSCLC, PD-L1 < 1%. No participant was enrolled and treated in Cohort 3.

Pre-assignment

Screening details:

"Study termination by sponsor" was used as the end of study reason after long-term follow-up was discontinued and enrollment closed. Study status is "completed" as participants received treatment per protocol, followed by safety follow-up. No further disease or survival follow-up was required.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

Not applicable

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort 1: Relapsed/refractory melanoma

Arm description:

Participants with relapsed/refractory melanoma, were administered SEA-CD40 10 micrograms per kilogram (mcg/kg) as an intravenous (IV) infusion on Day 1 and Day 22 of 42-day cycles along with Pembrolizumab 400 milligrams (mg) as an IV infusion on Day 8 of 42-day cycles.

Arm type	Experimental
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received Pembrolizumab 400 mg as an IV infusion on Day 8 of 42-day cycles.

Investigational medicinal product name	SEA-CD40
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received SEA-CD40 10 mcg/kg as an IV infusion on Day 1 and Day 22 of 42-day cycles.

Arm title	Cohort 2: Uveal melanoma

Arm description:

Participants with uveal melanoma, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 1 and Day 22 of 42-day cycles along with Pembrolizumab 400 mg as an IV infusion on Day 8 of 42-day cycles.

Arm type	Experimental

Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received Pembrolizumab 400 mg as an IV infusion on Day 8 of 42-day cycles.

Investigational medicinal product name	SEA-CD40
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received SEA-CD40 10 mcg/kg as an IV infusion on Day 1 and Day 22 of 42-day cycles.

Arm title	Cohort 4: NSCLC, PD-L1 1-49%

Arm description:

Participants with NSCLC, PD-L1 1-49%, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 3 of 21-day cycles along with Pembrolizumab 200 mg as an IV infusion on Day 1 of 21-day cycles and Pemetrexed 500 mg per meter square (/m^2) as an IV infusion on Day 1 of 21-day cycles and Carboplatin area under curve (AUC) 5 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of 21-day (Cycles 1–4).

Arm type	Experimental
Investigational medicinal product name	SEA-CD40
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received SEA-CD40 10 mcg/kg as an IV infusion on Day 3 of 21-day cycles.

Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received Pemetrexed 500 mg/m^2 as an IV infusion on Day 1 of 21-day cycles.

Investigational medicinal product name	Carboplatin AUC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received Carboplatin AUC 5 mg/mL/min as an IV infusion on Day 1 of 21-day (Cycles 1–4).

Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received Pembrolizumab 200 mg as an IV infusion on Day 1 of 21-day cycles.

Arm title	Cohort 5: NSCLC, PD-L1 < 1%

Arm description:	
Participants with NSCLC, PD-L1 <1%, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 3 of 21-day cycles along with Pembrolizumab 200 mg as an IV infusion on Day 1 of 21-day cycles and Pemetrexed 500 mg/m^2 as an IV infusion on Day 1 of 21-day cycles and Carboplatin AUC 5 mg/mL/min as an IV infusion on Day 1 of 21-day (Cycles 1–4).	
Arm type	Experimental
Investigational medicinal product name	SEA-CD40
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants received SEA-CD40 10 mcg/kg as an IV infusion on Day 3 of 21-day cycles.	
Investigational medicinal product name	Carboplatin AUC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants received Carboplatin AUC 5 mg/mL/min as an IV infusion on Day 1 of 21-day (Cycles 1–4).	
Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants received Pemetrexed 500 mg/m^2 as an IV infusion on Day 1 of 21-day cycles.	
Investigational medicinal product name	Pembrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Participants received Pembrolizumab 200 mg as an IV infusion on Day 1 of 21-day cycles.	

Number of subjects in period 1	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%
Started	21	39	9
Completed	0	0	0
Not completed	21	39	9
Consent withdrawn by subject	4	3	-
Unspecified	2	3	3
Adverse Events	11	8	3
Study termination by sponsor	3	25	3
Lost to follow-up	1	-	-

Number of subjects in period 1	Cohort 5: NSCLC, PD-L1 < 1%

Started	8
Completed	0
Not completed	8
Consent withdrawn by subject	2
Unspecified	2
Adverse Events	1
Study termination by sponsor	3
Lost to follow-up	-

Baseline characteristics

Reporting groups	
Reporting group title	Cohort 1: Relapsed/refractory melanoma
Reporting group description:	
Participants with relapsed/refractory melanoma, were administered SEA-CD40 10 micrograms per kilogram (mcg/kg) as an intravenous (IV) infusion on Day 1 and Day 22 of 42-day cycles along with Pembrolizumab 400 milligrams (mg) as an IV infusion on Day 8 of 42-day cycles.	
Reporting group title	Cohort 2: Uveal melanoma
Reporting group description:	
Participants with uveal melanoma, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 1 and Day 22 of 42-day cycles along with Pembrolizumab 400 mg as an IV infusion on Day 8 of 42-day cycles.	
Reporting group title	Cohort 4: NSCLC, PD-L1 1-49%
Reporting group description:	
Participants with NSCLC, PD-L1 1-49%, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 3 of 21-day cycles along with Pembrolizumab 200 mg as an IV infusion on Day 1 of 21-day cycles and Pemetrexed 500 mg per meter square (/m^2) as an IV infusion on Day 1 of 21-day cycles and Carboplatin area under curve (AUC) 5 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of 21-day (Cycles 1–4).	
Reporting group title	Cohort 5: NSCLC, PD-L1 < 1%
Reporting group description:	
Participants with NSCLC, PD-L1 <1%, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 3 of 21-day cycles along with Pembrolizumab 200 mg as an IV infusion on Day 1 of 21-day cycles and Pemetrexed 500 mg/m^2 as an IV infusion on Day 1 of 21-day cycles and Carboplatin AUC 5 mg/mL/min as an IV infusion on Day 1 of 21-day (Cycles 1–4).	

Reporting group values	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%
Number of subjects	21	39	9
Age Categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	64.3	62.2	64.6
standard deviation	± 11.6	± 12.4	± 9.2
Gender categorical Units: Subjects			
Male	12	19	5
Female	9	20	4
Ethnicity Units: Subjects			
Hispanic or Latino	3	0	0
Not Hispanic or Latino	16	38	9
Unknown or Not Reported	2	1	0
Race Units: Subjects			
Asian	1	0	0
Black or African American	0	0	0
White	16	39	9
Unknown or Not Reported	4	0	0

Reporting group values	Cohort 5: NSCLC, PD-L1 < 1%	Total	
Number of subjects	8	77	
Age Categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	66.8		
standard deviation	± 9.5	-	
Gender categorical Units: Subjects			
Male	6	42	
Female	2	35	
Ethnicity Units: Subjects			
Hispanic or Latino	1	4	
Not Hispanic or Latino	5	68	
Unknown or Not Reported	2	5	
Race Units: Subjects			
Asian	0	1	
Black or African American	1	1	
White	5	69	
Unknown or Not Reported	2	6	

End points

End points reporting groups

Reporting group title	Cohort 1: Relapsed/refractory melanoma
Reporting group description:	
Participants with relapsed/refractory melanoma, were administered SEA-CD40 10 micrograms per kilogram (mcg/kg) as an intravenous (IV) infusion on Day 1 and Day 22 of 42-day cycles along with Pembrolizumab 400 milligrams (mg) as an IV infusion on Day 8 of 42-day cycles.	
Reporting group title	Cohort 2: Uveal melanoma
Reporting group description:	
Participants with uveal melanoma, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 1 and Day 22 of 42-day cycles along with Pembrolizumab 400 mg as an IV infusion on Day 8 of 42-day cycles.	
Reporting group title	Cohort 4: NSCLC, PD-L1 1-49%
Reporting group description:	
Participants with NSCLC, PD-L1 1-49%, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 3 of 21-day cycles along with Pembrolizumab 200 mg as an IV infusion on Day 1 of 21-day cycles and Pemetrexed 500 mg per meter square (/m^2) as an IV infusion on Day 1 of 21-day cycles and Carboplatin area under curve (AUC) 5 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of 21-day (Cycles 1–4).	
Reporting group title	Cohort 5: NSCLC, PD-L1 < 1%
Reporting group description:	
Participants with NSCLC, PD-L1 <1%, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 3 of 21-day cycles along with Pembrolizumab 200 mg as an IV infusion on Day 1 of 21-day cycles and Pemetrexed 500 mg/m^2 as an IV infusion on Day 1 of 21-day cycles and Carboplatin AUC 5 mg/mL/min as an IV infusion on Day 1 of 21-day (Cycles 1–4).	

Primary: Confirmed Objective Response Rate (cORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) per Investigator Assessment

End point title	Confirmed Objective Response Rate (cORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) per Investigator Assessment[1]
End point description:	
cORR is defined as the percentage of participants achieving a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1. CR: disappearance of all target, non-target lesions, all lymph nodes must be non-pathological in size (<10 millimeter [mm] short axis), PR: at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters persistence of one or more non-target lesions. The response evaluable (RE) analysis set included all participants with measurable disease at baseline who received any amount of study drug and had at least one post-baseline disease assessment per RECIST v1.1 or discontinued study treatment. 99999 indicated that the upper and lower limit of 95% CI was not estimable since no participant had event.	
End point type	Primary
End point timeframe:	
From start of study treatment until CR or PR (maximum up to 15.2 months)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive data was planned for this endpoint.

End point values	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%	Cohort 5: NSCLC, PD-L1 < 1%
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	39	9	8
Units: Percentage of participants				
number (confidence interval 95%)	0 (-99999 to 99999)	5 (0.6 to 17.3)	44 (13.7 to 78.8)	25 (3.2 to 65.1)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Related TEAEs, Greater Than or Equal to (>=) Grade 3 TEAEs, Treatment Emergent Serious Adverse Event (TESAE), Treatment Related TESAE

End point title	Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Related TEAEs, Greater Than or Equal to (>=) Grade 3 TEAEs, Treatment Emergent Serious Adverse Event (TESAE), Treatment Related TESAE

End point description:

AE: untoward medical occurrence in participant administered medicinal product which doesn't necessarily have causal relationship with treatment. SAE: any AE that at any dose resulted in death, life threatening, required hospitalization/prolongation of hospitalisation, disabling/incapacitating, congenital anomaly/birth defects. AEs included SAEs,non-SAEs. TEAEs:newly occurring/worsening after 1st dose of treatment. Treatment related TEAEs: related to treatment; relatedness judged by investigator. TEAEs graded according to National Cancer Institute Common Terminology Criteria for AEs (NCI-CTCAE) v4.03 (grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threating, grade 5=fatal). TESAEs:any TEAE that at any dose suspected to cause death, life-threatening, required hospitalisation, disabling/incapacitating, congenital anomaly/birth defect. Treatment related TESAEs:related to treatment; relatedness judged by investigator. Safety analysis set: participants who received study drug.

End point type	Secondary

End point timeframe:

From first dose of the study treatment (Day 1) up to approximately 18.5 months

End point values	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%	Cohort 5: NSCLC, PD-L1 < 1%
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	39	9	8
Units: Participants				
TEAE	17	37	8	8
Treatment-related TEAE	16	32	8	8
>= Grade 3 TEAEs	7	7	7	6
TESAE	4	5	5	5
Treatment-related TESAE	2	2	3	3

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Grade Shift from Baseline to Maximum Post-Baseline in Serum Chemistry Laboratory Abnormalities Assessed by NCI CTCAE

End point title	Number of Participants With Grade Shift from Baseline to Maximum Post-Baseline in Serum Chemistry Laboratory Abnormalities Assessed by NCI CTCAE

End point description:

Number of participants with baseline (BL) laboratory values as per NCI-CTCAE grade (G) (grade 0=within normal limits, grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening) and corresponding changes/shift to worst maximum (max) CTC grades post baseline presented. Laboratory parameters evaluated: alanine aminotransferase (AAT) increased, albumin decreased, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, calcium corrected for albumin (CCA), creatinine increased, glomerular filtration rate (GFR) estimated decreased, glucose decreased, lactate dehydrogenase (LD) increased, potassium, sodium, total bilirubin (TB) increased. Baseline: last non-missing grade before 1st dose of study treatment. Worst post-baseline value: worst value post study treatment. Only those categories in which at least 1 participant had data in any reporting group were reported. Safety analysis set included participants who received study drug.

End point type	Secondary

End point timeframe:

Baseline up to approximately 15.8 months

End point values	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%	Cohort 5: NSCLC, PD-L1 < 1%
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	39	9	8
Units: Participants				
AAT-increased: BL Grade 0 to max post-BL Grade 1	2	7	3	3
AAT - increased: BL G0 to max post-BL G2	0	3	1	0
AAT - increased: BL G0 to max post-BL G3	0	1	0	0
AAT - increased: BL G1 to max post-BL G0	0	1	0	0
AAT - increased: BL G2 to max post-BL G0	0	1	0	0
Albumin-decreased: BL G0 to max post-BL G1	5	2	2	1
Albumin-decreased: BL G0 to max post-BL G2	1	0	1	1
Albumin-decreased: BL G1 to max post-BL G2	3	1	1	1
ALP - increased: BL G0 to max post-BL G1	4	9	1	1
ALP - increased: BL G1 to max post-BL G0	1	3	1	2
ALP - increased: BL G1 to max post-BL G2	1	0	0	0
ALP - increased: BL G2 to max post-BL G0	0	0	1	0
AST - increased: BL G0 to max post-BL Grade 1	5	14	3	4

AST - increased: BL G0 to max post-BL G2	1	2	1	0
AST - increased: BL G1 to max post-BL G0	0	2	0	0
AST - increased: BL G1 to max post-BL G2	0	1	0	0
CCA - decreased: BL G0 to max post-BL G1	2	1	4	1
CCA - decreased: BL G0 to max post-BL G2	0	0	1	2
CCA - decreased: BL G2 to max post-BL Grade 1	0	1	0	0
CCA - increased: BL G0 to max post-BL G1	0	9	0	0
Creatinine - increased: BL G0 to max post-BL G1	3	5	1	2
Creatinine-increased: BL G0 to max post-BL G2	1	2	0	0
Creatinine-increased: BL G0 to max post-BL G3	0	0	0	1
Creatinine-increased: BL G1 to max post-BL G2	0	1	0	0
Glucose-decreased: BL G0 to post-BL G1	0	3	0	2
LD - increased: BL G0 to max post-BL G1	3	22	3	4
LD - increased: BL G1 to max post-BL G0	1	0	0	0
Potassium-decreased: BL G0 to max post-BL G1	3	4	2	1
Potassium-decreased: BL G0 to max post-BL G3	0	0	0	1
Potassium-decreased: BL G1 to max post-BL G0	0	1	1	0
Potassium-increased: BL G0 to max post-BL G1	1	4	0	1
Potassium-increased: BL G0 to max post-BL G2	0	4	1	1
Sodium - decreased: BL G0 to max post-BL G1	7	10	3	3
Sodium - decreased: BL G0 to max post-BL G2	1	2	0	1
Sodium - decreased: BL G0 to max post-BL G3	0	1	0	0
Sodium - decreased: BL G1 to max post-BL G0	0	1	1	0
Sodium - decreased: BL G1 to max post-BL G2	0	1	0	0
TB - increased: BL G0 to max post-BL G1	1	2	0	0
TB - increased: BL G0 to max post-BL G3	1	1	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Grade Shift from Baseline to Maximum

Post-Baseline in Hematology Parameters Assessed by NCI CTCAE

End point title	Number of Participants With Grade Shift from Baseline to Maximum Post-Baseline in Hematology Parameters Assessed by NCI CTCAE

End point description:

In this endpoint, number of participants with baseline laboratory hematology values as per NCI-CTCAE grade (grade 0= within normal limits, grade 1=mild, grade 2=moderate, grade 3= severe, grade 4= life-threatening) and corresponding changes or shift to the worst CTC grades post baseline were presented. Laboratory parameters evaluated: hemoglobin (Hb)- decreased and increased, leukocytes- decreased and increased, lymphocytes- decreased and increased, neutrophils decreased, platelets decreased. Baseline was defined as last non-missing grade before first dose of study treatment and worst post-baseline value defined as worst value post study treatment. Only those categories in which at least 1 participant had data in any reporting group were reported. The safety analysis set included all participants who received any amount of study drug.

End point type	Secondary

End point timeframe:

Baseline up to approximately 15.8 months

End point values	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%	Cohort 5: NSCLC, PD-L1 < 1%
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	39	9	8
Units: Participants				
Hb - decreased: BL G0 to max post-BL G1	7	11	4	2
Hb - decreased: BL G0 to max post-BL G2	0	0	2	1
Hb - decreased: BL G0 to max post-BL G3	0	0	1	1
Hb - decreased: BL G1 to max post-BL G2	3	1	0	3
Hb - decreased: BL G1 to max post-BL G3	1	0	1	1
Hb - decreased: BL G2 to max post-BL G1	0	1	0	0
Hb - increased: BL G0 to max post-BL G1	0	2	0	0
Leukocytes-decreased: BL G0 to max post-BL G1	1	3	2	4
Leukocytes-decreased: BL G0 to max post-BL G2	0	0	1	0
Leukocytes-decreased: BL G0 to max post-BL G3	0	0	1	0
Lymphocytes-decreased: BL G0 to post-BL G1	2	9	1	1
Lymphocytes-decreased: BL G0 to max post-BL G2	4	0	2	0
Lymphocytes-decreased: BL G0 to max post-BL G3	1	1	1	0
Lymphocytes-decreased: BL G0 to max post-BL G4	0	0	1	0
Lymphocytes-decreased: BL G1 to max post-BL G2	1	1	0	1
Lymphocytes-decreased: BL G1 to max post-BL G3	0	0	0	1

Lymphocytes-decreased: BL G2 to max post-BL G3	0	2	1	0
Lymphocytes-decreased: BL G3 to max post-BL G4	0	0	0	1
Lymphocytes-increased: BL G0 to max post-BL G2	0	1	0	0
Neutrophils-decreased: BL G0 to max post-BL G1	1	2	0	0
Neutrophils-decreased: BL G0 to max post-BL G2	0	0	2	1
Neutrophils-decreased: BL G0 to max post-BL G3	0	0	1	0
Platelets-decreased: BL G0 to max post-BL G1	1	1	4	3

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Treatment Interruptions, Dose Reductions, Treatment Discontinuations due to Adverse Events

End point title	Number of Participants With Treatment Interruptions, Dose Reductions, Treatment Discontinuations due to Adverse Events

End point description:

An AE is defined as any untoward medical occurrence in participant/clinical investigational participant administered medicinal product which doesn't necessarily have causal relationship with treatment. Number of participants with dose interruption (SEA-CD40 treatment being temporarily stopped), dose reduction (SEA-CD40 decrease in dose) and dose discontinuation (SEA-CD40 treatment permanently stopped) due to adverse events were reported in this outcome measure. The safety analysis set included all participants who received any amount of study drug.

End point type	Secondary

End point timeframe:

From first dose of the study treatment (Day 1) up to approximately 18.5 months

End point values	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%	Cohort 5: NSCLC, PD-L1 < 1%
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	39	9	8
Units: Participants				
Treatment interruptions	1	5	2	1
Dose reductions	0	0	0	0
Treatment discontinuations	2	0	2	1

Statistical analyses

No statistical analyses for this end point

Secondary: Disease Control Rate (DCR) per Investigator Assessment

End point title	Disease Control Rate (DCR) per Investigator Assessment

End point description:

DCR is defined as the percentage of participants who achieved a confirmed CR or PR according to RECIST v1.1 as assessed by the investigator or met the stable disease (SD) criteria at least once after start of study treatment at a minimum interval of 5 weeks. CR: disappearance of all target, non-target lesions, all lymph nodes must be non-pathological in size (<10 mm short axis), PR: at least 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters persistence of one or more non-target lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase in lesions to qualify for progressive disease (PD) referring smallest sum diameter, PD: at least 20% increase (including absolute increase of at least 5 mm) in sum of diameters of target lesions, taking reference smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. RE analysis set was analysed.

End point type	Secondary

End point timeframe:

From the first dose of study treatment until the first documented CR, PR or SD or new anticancer therapies or death, whichever occurred first (maximum up to 23.6 months)

End point values	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%	Cohort 5: NSCLC, PD-L1 < 1%
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	39	9	8
Units: Percentage of participants				
number (confidence interval 95%)	48 (25.7 to 70.2)	62 (44.6 to 76.6)	67 (29.9 to 92.5)	88 (47.3 to 99.7)

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR) per Investigator Assessment

End point title	Duration of Response (DOR) per Investigator Assessment

End point description:

DOR:time from 1st documentation of OR(confirmed CR/PR)to 1st documentation of PD/death,whichever occurred 1st.Per RECIST v1.1,CR: disappearance of target lesions.Pathological lymph nodes must have reduction in short axis to <10mm.PR:>=30% decrease in sum of diameters of target lesions.Participants with no PD,still on study at time of analysis/removed from study prior to PD documentation censored at last disease assessment documenting absence of PD.Participants starting anticancer treatment prior to PD documentation censored at last disease assessment prior to treatment.PD:>=20% increase in sum of diameters of target lesions,with 0.5cm increase.Appearance of 1+ new lesions.Kaplan-Meier method.RE analysis set.Subjects Analyzed=participants with confirmed CR/PR. 77777:median, upper limit (UL) 95%CI not estimable due to less number of participants. 88888:UL 95%CI not estimable due to less number of participants. 99999:lower and UL of 95%CI not estimable due to less number of participants.

End point type	Secondary

End point timeframe:

From the first documentation of CR or PR to PD or death due to any cause or censoring, whichever occurred first (maximum up to 23.6 months)

End point values	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%	Cohort 5: NSCLC, PD-L1 < 1%
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[2]	2	4	2
Units: Months				
median (confidence interval 95%)	(to)	77777 (5.6 to 77777)	11.1 (9.9 to 88888)	2.1 (-99999 to 99999)

Notes:

[2] - No participant had an event.

Statistical analyses

No statistical analyses for this end point

Secondary: Progression Free Survival (PFS) per Investigator Assessment

End point title	Progression Free Survival (PFS) per Investigator Assessment

End point description:

PFS: time from start of study treatment to first documentation of PD by RECIST v1.1 or death due to any cause, whichever occurred first. Participants with no PD and were still on study at time of analysis/were removed from study prior to documentation of PD were censored at date of last disease assessment documenting absence of PD. Participants who started new anticancer treatment prior to documentation of PD were censored at date of last disease assessment prior to start of new treatment. PD: at least 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study. In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least 0.5cm. Appearance of one or more new lesions was also considered progression. Kaplan-Meier method used. Full analysis set (FAS) included participants who received study drug. 88888: upper limit of 95% confidence interval was not estimable due to insufficient number of participants with events.

End point type	Secondary

End point timeframe:

From first dose of study treatment to the date of PD or death due to any cause or censoring, whichever occurred first (maximum up to 23.6 months)

End point values	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%	Cohort 5: NSCLC, PD-L1 < 1%
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	39	9	8
Units: Months				
median (confidence interval 95%)	1.6 (1.4 to 2.9)	4.0 (1.4 to 8.2)	13.8 (1.4 to 88888)	5.5 (1.4 to 88888)

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)

End point description:

OS is defined as the time from the start of study treatment to date of death due to any cause. In the absence of death, survival time was censored at the last date the participant was known to be alive. Kaplan-Meier method was used for analysis. The FAS included all participants who received any amount of study drug. 77777: Median and upper limit of the 95% confidence interval was not estimable due to insufficient number of participants with events. 88888: Upper limit of the 95% confidence interval was not estimable due to insufficient number of participants with events.

End point type	Secondary

End point timeframe:

From start of study treatment to death due to any cause or censoring, (maximum up to 23.6 months)

End point values	Cohort 1: Relapsed/refractory melanoma	Cohort 2: Uveal melanoma	Cohort 4: NSCLC, PD-L1 1-49%	Cohort 5: NSCLC, PD-L1 < 1%
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	39	9	8
Units: Months				
median (confidence interval 95%)	11.0 (5.3 to 18.7)	77777 (16.7 to 77777)	18.0 (2.5 to 88888)	77777 (3.2 to 77777)

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of the study treatment (Day 1) up to approximately 18.5 months for SAEs, 16.5 months for non-SAEs and 23.6 months for death

Adverse event reporting additional description:

Same event may appear as both non-SAE and SAE but what is presented are distinct events. Event may be categorised as serious in 1 participant and non-serious in other, or participant may have experienced both serious and non-serious event. The safety analysis set included all participants who received any amount of study drug.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	26.1

Reporting groups

Reporting group title	Cohort 1: Relapsed/refractory melanoma

Reporting group description:

Participants with relapsed/refractory melanoma, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 1 and Day 22 of 42-day cycles along with Pembrolizumab 400 mg as an IV infusion on Day 8 of 42-day cycles.

Reporting group title	Cohort 5: NSCLC, PD-L1 < 1%

Reporting group description:

Participants with NSCLC, PD-L1 <1%, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 3 of 21-day cycles along with Pembrolizumab 200 mg as an IV infusion on Day 1 of 21-day cycles and Pemetrexed 500 mg/m^2 as an IV infusion on Day 1 of 21-day cycles and Carboplatin AUC 5 mg/mL/min as an IV infusion on Day 1 of 21-day (Cycles 1–4).

Reporting group title	Cohort 4: NSCLC, PD-L1 1-49%

Reporting group description:

Participants with NSCLC, PD-L1 1-49%, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 3 of 21-day cycles along with Pembrolizumab 200 mg as an IV infusion on Day 1 of 21-day cycles and Pemetrexed 500 mg/m^2 as an IV infusion on Day 1 of 21-day cycles and Carboplatin AUC 5 mg/mL/min as an IV infusion on Day 1 of 21-day (Cycles 1–4).

Reporting group title	Cohort 2: Uveal melanoma

Reporting group description:

Participants with uveal melanoma, were administered SEA-CD40 10 mcg/kg as an IV infusion on Day 1 and Day 22 of 42-day cycles along with Pembrolizumab 400 mg as an IV infusion on Day 8 of 42-day cycles.

Serious adverse events	Cohort 1: Relapsed/refractory melanoma	Cohort 5: NSCLC, PD-L1 < 1%	Cohort 4: NSCLC, PD-L1 1-49%
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 21 (19.05%)	5 / 8 (62.50%)	5 / 9 (55.56%)
number of deaths (all causes)	11	1	3
number of deaths resulting from adverse events	1	1	1
Vascular disorders			
Peripheral arterial occlusive disease			

subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hypotension			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery stenosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pulmonary embolism			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	2 / 2	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hypophysitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 21 (0.00%)	2 / 8 (25.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypocalcaemia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort 2: Uveal melanoma		
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 39 (12.82%)		
number of deaths (all causes)	8		
number of deaths resulting from adverse events	0		
Vascular disorders			
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral artery stenosis			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoxia			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary oedema			

subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infusion related reaction			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Overdose			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Dizziness			

subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestine perforation			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Hypophysitis			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthralgia			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clostridium difficile colitis			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypocalcaemia			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic ketoacidosis			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cohort 1: Relapsed/refractory melanoma	Cohort 5: NSCLC, PD-L1 < 1%	Cohort 4: NSCLC, PD-L1 1-49%
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 21 (80.95%)	7 / 8 (87.50%)	8 / 9 (88.89%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Vascular disorders			
Flushing			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hot flush			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	3
Hypertension			
subjects affected / exposed	3 / 21 (14.29%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Hypotension			
subjects affected / exposed	5 / 21 (23.81%)	2 / 8 (25.00%)	2 / 9 (22.22%)
occurrences (all)	6	3	2

Phlebitis			
subjects affected / exposed	2 / 21 (9.52%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Chest discomfort			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Chills			
subjects affected / exposed	6 / 21 (28.57%)	3 / 8 (37.50%)	2 / 9 (22.22%)
occurrences (all)	8	4	4
Chest pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	4 / 21 (19.05%)	3 / 8 (37.50%)	7 / 9 (77.78%)
occurrences (all)	5	4	9
Pyrexia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1
Oedema peripheral			
subjects affected / exposed	3 / 21 (14.29%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	5	1	0
Non-cardiac chest pain			
subjects affected / exposed	2 / 21 (9.52%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Malaise			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Vulvovaginal rash			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal			

disorders			
Dyspnoea			
subjects affected / exposed	2 / 21 (9.52%)	3 / 8 (37.50%)	3 / 9 (33.33%)
occurrences (all)	2	4	3
Dysphonia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	2 / 21 (9.52%)	3 / 8 (37.50%)	1 / 9 (11.11%)
occurrences (all)	2	3	1
Epistaxis			
subjects affected / exposed	0 / 21 (0.00%)	2 / 8 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Haemoptysis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Hypoxia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	4	0	0
Hiccups			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Nasal congestion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Productive cough			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Pulmonary embolism			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Wheezing			

subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Rhinitis allergic			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Confusional state			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Depression			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Insomnia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1
Irritability			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 21 (0.00%)	2 / 8 (25.00%)	1 / 9 (11.11%)
occurrences (all)	0	5	1
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	1	4
Alanine aminotransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	2	6
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Platelet count decreased			

subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Weight decreased			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	3 / 9 (33.33%)
occurrences (all)	1	1	3
White blood cell count decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Procedural pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Infusion related reaction			
subjects affected / exposed	12 / 21 (57.14%)	4 / 8 (50.00%)	3 / 9 (33.33%)
occurrences (all)	17	5	6
Fall			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Skull fractured base			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Balance disorder			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Memory impairment			

subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Dysgeusia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Headache			
subjects affected / exposed	4 / 21 (19.05%)	2 / 8 (25.00%)	4 / 9 (44.44%)
occurrences (all)	5	3	4
Dizziness			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	3 / 9 (33.33%)
occurrences (all)	2	1	5
Syncope			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Somnolence			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Radiculopathy			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Metabolic encephalopathy			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 21 (14.29%)	6 / 8 (75.00%)	4 / 9 (44.44%)
occurrences (all)	3	9	6
Neutropenia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	3 / 9 (33.33%)
occurrences (all)	0	1	5
Ear and labyrinth disorders			
Ear pain			

subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Hypoacusis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Eye disorders			
Dry eye			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Lacrimation increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Vision blurred			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Visual impairment			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	3 / 21 (14.29%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	2 / 21 (9.52%)	3 / 8 (37.50%)	1 / 9 (11.11%)
occurrences (all)	3	3	2
Diarrhoea			
subjects affected / exposed	6 / 21 (28.57%)	3 / 8 (37.50%)	3 / 9 (33.33%)
occurrences (all)	9	3	5
Defaecation urgency			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dry mouth			

subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Eructation			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	2 / 21 (9.52%)	1 / 8 (12.50%)	2 / 9 (22.22%)
occurrences (all)	2	1	2
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	9 / 21 (42.86%)	3 / 8 (37.50%)	7 / 9 (77.78%)
occurrences (all)	15	3	9
Stomatitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	2 / 9 (22.22%)
occurrences (all)	0	2	2
Vomiting			
subjects affected / exposed	6 / 21 (28.57%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	8	1	1
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dry skin			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Decubitus ulcer			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Eczema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Erythema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Pain of skin			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Rash maculo-papular			
subjects affected / exposed	2 / 21 (9.52%)	3 / 8 (37.50%)	1 / 9 (11.11%)
occurrences (all)	2	3	1
Pruritus			
subjects affected / exposed	3 / 21 (14.29%)	0 / 8 (0.00%)	2 / 9 (22.22%)
occurrences (all)	3	0	2
Skin haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Skin ulcer			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Pollakiuria			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Urinary retention			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Hyperthyroidism			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			

Myalgia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	5	0	2
Pain in extremity			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	3	1
Arthralgia			
subjects affected / exposed	3 / 21 (14.29%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	4	1	0
Back pain			
subjects affected / exposed	6 / 21 (28.57%)	3 / 8 (37.50%)	0 / 9 (0.00%)
occurrences (all)	7	3	0
Muscular weakness			
subjects affected / exposed	2 / 21 (9.52%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	2	1	1
Infections and infestations			
COVID-19			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	2 / 9 (22.22%)
occurrences (all)	1	1	2
Rash pustular			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Pneumonia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Cellulitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Clostridium difficile colitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Oral candidiasis			
subjects affected / exposed	0 / 21 (0.00%)	2 / 8 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	3	0
Urinary tract infection			

subjects affected / exposed	2 / 21 (9.52%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Suspected COVID-19			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Rhinitis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 21 (9.52%)	1 / 8 (12.50%)	3 / 9 (33.33%)
occurrences (all)	2	1	3
Dehydration			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	3 / 9 (33.33%)
occurrences (all)	1	1	4
Hyperglycaemia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	4	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 21 (0.00%)	2 / 8 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	7	0
Hypokalaemia			
subjects affected / exposed	0 / 21 (0.00%)	2 / 8 (25.00%)	1 / 9 (11.11%)
occurrences (all)	0	3	1
Hyponatraemia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	4	0	0
Hypomagnesaemia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	1	1	0

Hypophosphataemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Malnutrition			
subjects affected / exposed	0 / 21 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	Cohort 2: Uveal melanoma		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	37 / 39 (94.87%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Flushing			
subjects affected / exposed	2 / 39 (5.13%)		
occurrences (all)	5		
Hot flush			
subjects affected / exposed	4 / 39 (10.26%)		
occurrences (all)	4		
Hypertension			
subjects affected / exposed	2 / 39 (5.13%)		
occurrences (all)	2		
Hypotension			
subjects affected / exposed	3 / 39 (7.69%)		
occurrences (all)	3		
Phlebitis			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Chest discomfort			

subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Chills			
subjects affected / exposed	11 / 39 (28.21%)		
occurrences (all)	16		
Chest pain			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Fatigue			
subjects affected / exposed	24 / 39 (61.54%)		
occurrences (all)	32		
Pyrexia			
subjects affected / exposed	5 / 39 (12.82%)		
occurrences (all)	5		
Oedema peripheral			
subjects affected / exposed	2 / 39 (5.13%)		
occurrences (all)	3		
Non-cardiac chest pain			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences (all)	1		
Malaise			
subjects affected / exposed	3 / 39 (7.69%)		
occurrences (all)	3		
Reproductive system and breast disorders			
Vulvovaginal rash			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	4 / 39 (10.26%)		
occurrences (all)	4		
Dysphonia			
subjects affected / exposed	2 / 39 (5.13%)		
occurrences (all)	2		
Cough			

subjects affected / exposed	8 / 39 (20.51%)		
occurrences (all)	9		
Epistaxis			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Haemoptysis			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Hypoxia			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Hiccups			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Nasal congestion			
subjects affected / exposed	4 / 39 (10.26%)		
occurrences (all)	4		
Oropharyngeal pain			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences (all)	1		
Productive cough			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences (all)	2		
Pulmonary embolism			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences (all)	1		
Wheezing			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Rhinitis allergic			
subjects affected / exposed	4 / 39 (10.26%)		
occurrences (all)	4		
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		

Confusional state subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1		
Depression subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1		
Insomnia subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2		
Irritability subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Investigations Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 5		
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	6 / 39 (15.38%) 8		
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1		
Platelet count decreased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Weight decreased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Injury, poisoning and procedural complications			

Contusion subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2		
Procedural pain subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Infusion related reaction subjects affected / exposed occurrences (all)	11 / 39 (28.21%) 23		
Fall subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1		
Skull fractured base subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Cardiac disorders Tachycardia subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1		
Nervous system disorders Amnesia subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Balance disorder subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Memory impairment subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Dysgeusia subjects affected / exposed occurrences (all)	4 / 39 (10.26%) 4		
Headache subjects affected / exposed occurrences (all)	13 / 39 (33.33%) 18		
Dizziness			

subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 5		
Syncope subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Somnolence subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2		
Radiculopathy subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Metabolic encephalopathy subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3		
Neutropenia subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1		
Hypoacusis subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Eye disorders Dry eye subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1		
Lacrimation increased			

subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Vision blurred			
subjects affected / exposed	2 / 39 (5.13%)		
occurrences (all)	2		
Visual impairment			
subjects affected / exposed	2 / 39 (5.13%)		
occurrences (all)	2		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	8 / 39 (20.51%)		
occurrences (all)	10		
Abdominal pain upper			
subjects affected / exposed	2 / 39 (5.13%)		
occurrences (all)	3		
Constipation			
subjects affected / exposed	15 / 39 (38.46%)		
occurrences (all)	16		
Diarrhoea			
subjects affected / exposed	9 / 39 (23.08%)		
occurrences (all)	10		
Defaecation urgency			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Dry mouth			
subjects affected / exposed	5 / 39 (12.82%)		
occurrences (all)	5		
Eructation			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	2 / 39 (5.13%)		
occurrences (all)	2		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		

Immune-mediated enterocolitis subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0			
Nausea subjects affected / exposed occurrences (all)	16 / 39 (41.03%) 28			
Stomatitis subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1			
Vomiting subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 4			
Skin and subcutaneous tissue disorders Blister subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0			
Dry skin subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0			
Decubitus ulcer subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0			
Eczema subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 5			
Erythema subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0			
Pain of skin subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0			
Rash maculo-papular subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 5			
Pruritus				

subjects affected / exposed	7 / 39 (17.95%)		
occurrences (all)	7		
Skin haemorrhage			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Skin ulcer			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Pollakiuria			
subjects affected / exposed	2 / 39 (5.13%)		
occurrences (all)	2		
Urinary retention			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences (all)	1		
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	6 / 39 (15.38%)		
occurrences (all)	6		
Hyperthyroidism			
subjects affected / exposed	3 / 39 (7.69%)		
occurrences (all)	3		
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	6 / 39 (15.38%)		
occurrences (all)	6		
Pain in extremity			
subjects affected / exposed	6 / 39 (15.38%)		
occurrences (all)	10		
Arthralgia			
subjects affected / exposed	3 / 39 (7.69%)		
occurrences (all)	3		
Back pain			

subjects affected / exposed	3 / 39 (7.69%)		
occurrences (all)	3		
Muscular weakness			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences (all)	2		
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Rash pustular			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Clostridium difficile colitis			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Oral candidiasis			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	3 / 39 (7.69%)		
occurrences (all)	3		
Suspected COVID-19			
subjects affected / exposed	0 / 39 (0.00%)		
occurrences (all)	0		
Sinusitis			
subjects affected / exposed	1 / 39 (2.56%)		
occurrences (all)	1		

Rhinitis subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2		
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	7 / 39 (17.95%) 7		
Dehydration subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1		
Hyperglycaemia subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2		
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		
Hypokalaemia subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3		
Hyponatraemia subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 4		
Hypomagnesaemia subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1		
Hypophosphataemia subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2		
Malnutrition subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 June 2021	Changed reporting period for all SAEs to 90 days post-last dose.
04 April 2022	Chemistry and thyroid panels were added to assessments required for the first follow-up visit. Text was updated/added to collect SAEs for 90 days after the last study treatment and or AEs will be collected through the first follow-up visit. If a subject started a new anticancer therapy, collection of SAEs that were not related to study treatment and or AEs may be stopped 30 days after the cessation of study treatment. Study treatment-related SAEs that occurred after the safety reporting period was also reported to the sponsor. New section added for management of ocular events. Changed the pregnancy reporting timeline from within 48 hours to within 24 hours of becoming aware of a pregnancy.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported